Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - A short review

Pharmacology Biochemistry and Behavior

Volumn 90, Issue 4, 2008, Pages 501-511

  Svíženská, Ivana ^a   Dubový, Petr ^a   Šulcová, Alexandra ^b  

^a Department of Anatomy   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Cannabinoid; CB receptors; Endocannabinoid system; Nervous system; Therapeutic potential

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; GUANINE NUCLEOTIDE BINDING PROTEIN; METHAMPHETAMINE; MITOGEN ACTIVATED PROTEIN KINASE; N ARACHIDONOYLDOPAMINE; NOLADIN ETHER; RIMONABANT; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VIRHODAMINE;

ANALGESIA; ANTINOCICEPTION; BASAL GANGLION; BRAIN STEM; CEREBELLUM; CLINICAL TRIAL; HIPPOCAMPUS; HUMAN; IMMUNOHISTOCHEMISTRY; NERVOUS SYSTEM; NEUROPROTECTION; NONHUMAN; OLFACTORY NUCLEUS; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RECEPTOR DENSITY; REVIEW; SPINAL CORD; SPINAL GANGLION; TELENCEPHALON;

ANIMALS; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; LIGANDS; NERVOUS SYSTEM; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 48749103773     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.05.010     Document Type: Review

References (224)

1. Abood M.E., and Martin B.R. Neurobiology of marijuana abuse. Trends Pharmacol Sci 13 (1992) 201-206
2. Ahluwalia J., Urban L., Capogna M., Bevan S., and Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience 100 (2000) 685-688
3. Alberich Jorda M., Rayman N., Tas M., Verbakel S.E., Battista N., van Lom K., et al. The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104 (2004) 526-534
4. Amaya F., Shimosato G., Kawasaki Y., Hashimoto S., Tanaka Y., Ji R.R., et al. Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 124 (2006) 175-183
5. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 58 (1999) 315-348
6. Ashton J.C., Friberg D., Darlington C.L., and Smith P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 396 (2006) 113-116
7. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15 (2001) 300-302
8. Baker D., Pryce G., Giovannoni G., and Thompson A.J. The therapeutic potential of cannabis. Lancet Neurol 2 (2003) 291-298
9. Baker D., Pryce G., Davies W.L., and Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27 (2006) 1-4
10. Barth F., and Rinaldi-Carmona M. The development of cannabinoid antagonists. Curr Med Chem 6 (1999) 745-755
11. Baskfield C.Y., Martin B.R., and Wiley J.L. Differential effects of D9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice. J Pharmacol Exp Ther 309 (2004) 86-91
12. Begg M., Pacher P., Bátkai S., Osei-Hyiaman D., Offertáler L., Mo F.M., et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 106 (2005) 133-145
13. Behbehani M.M. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 46 (1995) 575-605
14. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
15. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 108 (2000) 169-190
16. Berger C., Schmid P.C., Schabitz W.R., Wolf M., Schwab S., and Schmid H.H.O. Massive accumulation of N-acylethanolamines after stroke R cell signalling in acute cerebral ischemia?. J Neurochem 88 (2004) 1159-1167
17. Block R.I., Farinpour R., and Braverman K. Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. Pharmacol Biochem Behav 43 (1992) 907-917
18. Bramblett R.D., Panu A.M., Ballesteros J.A., and Reggio P.H. Construction of a 3D model of the cannabinoids CB1 receptor: determination of the helix ends and helix orientation. Life Sci 56 (1995) 1971-1982
19. Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Vogt L.J., and Sim-Selley L.J. Chronic Δ9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73 (1999) 2447-2459
20. Bridges D., Ahmad K., and Rice A.S. The synthetic cannabinoid WIN55, 212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133 (2001) 586-594
21. Bridges D., Rice A.S.C., Egertova M., Elphick M.R., Winter J., and Michael G.J. Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience 119 (2003) 803-812
22. Cadoni C., Pisanu A., Solinas M., Acquas E., and Di Chiara G. Behavioural sensitization after repeated exposure to delta(9)-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology 158 (2001) 259-266
23. Caenazzo L., Hoehe M.R., Hsieh W.T., Berrettini W.H., Bonner T.I., and Gershon E.S. HindIII identifies a two allele DNA polymorphism of the human cannabinoid receptor gene (CNR). Nucleic Acids Res 11 (1991) 4798
24. Caffarel M.M., Sarrió D., Palacios J., Guzmán M., and Sánchez C. Δ9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 66 (2006) 6615-6621
25. Calignano A., La Rana G., Giuffrida A., and Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 394 (1998) 277-281
26. Calignano A., La Rana G., and Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419 (2001) 191-198
27. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., and Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int J Immunopharmacol 2 (2002) 69-82
28. Carracedo A., Gironella M., Lorente M., Garcia S., Guzmán M., Velasco G., et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 66 (2006) 6748-6755
29. Castle D., and Murray R. Marijuana and madness (2004), Cambridge University Press
30. Chait D., and Perry J.L. Acute and residual effects of alcohol and marijuana smoking, alone and in combination, on mood and performance. Psychopharmacology 115 (1994) 340-349
31. Chakrabarti A., Onaivi E.S., and Chaudhuri G. Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein. DNA Seq 5 (1995) 385-388
32. Chan G.C.K., Hinds T.R., Impey S., and Storm D.R. Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. J Neurosci 18 (1998) 5322-5332
33. Chaperon F., and Thiébot M.H. Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13 (1999) 243-281
34. Childers S.R., and Breivogel C.S. Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend 51 (1998) 173-187
35. Compton D.R., Aceto M.D., Lowe J., and Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277 (1996) 586-594
36. Condie R., Herring A., Koh W.S., Lee M., and Kaminski N.E. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem 271 (1996) 13175-13183
37. Cook S.A., Lowe J.A., and Martin B.R. CB1 receptor antagonist precipitates withdrawal in mice exposed to Δ9-tetrahydrocannabinol. J Pharmacol Exp Ther 285 (1998) 1150-1156
38. Cota D., Marsicano G., Tschop M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (2003) 423-431
39. Court J.M. Cannabis and brain function. J Paediatr Child Health 34 (1998) 1-5
40. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98 (2001) 9371-9376
41. Crawley J.N., Corwin R.L., Robinson J.K., Felder C.C., Devane W.A., and Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomobility and hypothermia in-vivo in rodents. Pharmacol Biochem Behav 46 (1993) 967-972
42. Cristino L., de Petrocellis L., Pryce G., Baker D., Guglielmotti V., and Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139 (2006) 1405-1415
43. Croci T., Manara L., Aureggi G., Guagnini F., Rinaldi-Carmona M., Maffrand J.P., et al. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol 125 (1998) 1393-1395
44. Derocq J.M., Segui M., Marchand J., Le Fur G., and Casellas P. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 369 (1995) 177-182
45. Deutsch D.G., and Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46 (1993) 791-796
46. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of cannabinoid receptor in the brain. Mol Pharmacol 34 (1988) 605-613
47. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
48. Di Marzo V., and Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 18 (2007) 129-140
49. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., and Martin B.R. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Curr Med Chem 6 (1999) 721-744
50. 2 receptor-mediated actions of anandamide in mouse brain. J Neurochem 75 (2000) 2434-2444
51. Egertova M., and Elphick M.R. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB1. J Comp Neurol 422 (2000) 159
52. Farquhar-Smith W.P., Egertova M., Bradbury E.J., McMahon S.B., Rice A.S., and Elphick M.R. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 15 (2000) 510-521
53. Fattore L., Cossu G., Martellota C.M., and Fratta W. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology (Berl) 156 (2001) 410-416
54. Fattore L., Spano M.S., Altea S., Angius F., Fadda P., and Fratta W. Cannabinoid self-administration in rats: sex differences and influence of ovarian function. Br J Pharmacol 152 (2007) 795-804
55. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48 (1995) 443-450
56. Fernández-Ruiz J., Romero J., Velasco G., Tolón R.M., Ramos J.A., and Guzmán M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends Pharmacol Sci 28 (2007) 39-45
57. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., and Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett 513 (2002) 294-298
58. Fonseca F.R., Del Arco I., Martín-Calderón J.L., Gorriti M.A., and Navarro M. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 5 (1998) 483-501
59. Forget B., Hamon M., and Thiébot M.H. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology 181 (2005) 722-734
60. Fowler C.J. Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, "entourage" compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid psychotropic effects. Brain Res Rev 41 (2003) 26-43
61. Fowler C.h.J., Holt S., Nilsson O., Jonsson K.O., Tiger G., and Jacobsson S.O.P. The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav 81 (2005) 248-262
62. Fride E., and Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist Δ9-tetrahydrocannabinol. J Pharmacol Exp Ther 272 (1993) 313-314
63. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232 (1995) 54-61
64. Gallant M., Dufresne C., Gareau Y., Guay D., Leblanc Y., Prasit P., et al. New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg Med Chem Lett 6 (1996) 2263-2268
65. Gaoni Y., and Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86 (1964) 1646-1647
66. Gareau Y., Dufresne C., Gallant M., Rochette C., Sawyer N., Slipetz D.M., et al. Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg Med Chem Lett 6 (1996) 189-194
67. Gelfand G.E., and Cannon C.P. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 47 (2006) 1919-1926
68. Gifford A.N., Samiian L., Gatley S.J., and Ashby C.R. Examination of the effect of the cannabinoid receptor agonists, CP55, 940, on electrically evoked transmitter release from rat brain slices. Eur J Pharmacol 324 (1997) 187-192
69. Glass M., and Northup J.K. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol 56 (1999) 1362-1369
70. Glass M., Faull R.L., and Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56 (1993) 523-527
71. Glass M., Dragunow M., and Faull R.L.M. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77 (1997) 299-318
72. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071 (2006) 10-23
73. González S., Cebeira M., and Fernández-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 81 (2005) 300-318
74. Grant I., and Cahn B.R. Cannabis and endocannabinoid modulators: therapeutic promises and challenges. Clin Neurosci Res 5 (2005) 185-199
75. Griffin G., Fernando S.R., Ross R.A., McKay N.G., Ashford M.L.J., Shire D., et al. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 339 (1997) 53-61
76. Griffin G., Wray E.J., Tao Q., McAllister S.D., Rorrer W.K., Aung M., et al. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528, further evidence for CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377 (1999) 117-125
77. In: Grotenhermen F., and Russo E. (Eds). Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (2002), Haworth Press, Binghamton, NY
78. Grundy R.I. Therapeutic potential of cannabinoids in neuroprotection. Expert Opin Investig Drugs 11 (2002) 1365-1374
79. Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 3 (2003) 745-755
80. Hampson A. Cannabinoids as neuroprotectants against ischemia. In: Grotenhermen F., and Russo E. (Eds). Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (2002), Haworth Press, Binghamton, NY 101-110
81. Hansen H.H., Azcoitia I., Pons S., Romero J., García-Segura L.M., Ramos J.A., et al. Blockade of cannabinoid CB1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J Neurochem 82 (2002) 154-158
82. Hanuš L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., et al. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 96 (1999) 14228-14233
83. Hanuš L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98 (2001) 3662-3665
84. Heishman S.J., Arasteh K., and Stitzer M.L. Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav 58 (1997) 93-101
85. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87 (1990) 1932-1936
86. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11 (1991) 563-583
87. Herkenham M., Lynn A.B., de Costa B.R., and Richfield E.K. Neuronal localization of cannabinoid receptors in basal ganglia of the rat. Brain Res 547 (1991) 267-274
88. + channels. Receptors Channels 6 (1999) 363-374
89. Hoehe M.R., Caenazzo L., Martinez M.M., Hsieh W.T., Modi W.S., Gershon E.S., et al. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol 3 (1991) 880-885
90. Hohmann A.G., and Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92 (1999) 1171-1175
91. Hohmann A.G., and Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90 (1999) 923-931
92. Hohmann A.G., Martin W.J., Tsou K., and Walker J.M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci 56 (1995) 2111-2118
93. Hohmann A.G., Tsou K., and Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol 81 (1999) 575-583
94. Hohmann A.G., Farthing J.N., Zvonok A.M., and Makriyannis A. Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308 (2004) 446-453
95. Howlett A.C. Cannabinoid inhibition of adenylate cyclase: biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 27 (1985) 429-436
96. Howlett A.C. Inhibition of neuroblastoma adenylyl cyclase by cannabinoid and nantradol compounds. Life Sci 35 (1984) 1803-1810
97. Howlett A.C., and Fleming R.M. Cannabinoid inhibition of adenylate cyclase: pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26 (1984) 532-538
98. Howlett A.C., and Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids 108 (2000) 53-70
99. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29 (1986) 307-313
100. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 (2002;) 1161-1202
101. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza R., et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 99 (2002) 8400-8405
102. Huestis M.A. Human cannabinoid pharmacokinetics. Chem Biodivers 4 (2007) 1770-1804
103. Huffman J.W. CB2 receptor ligands. Mini Rev Med Chem 5 (2005) 641-649
104. Huffman J.W., Yu S., Showalter V., Abood M.E., Wiley J.L., Compton D.R., et al. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39 (1996) 3875-3877
105. Ibrahim M.M., Deng H., Zvonok A., Cockayne D.A., Kwan J., Mata H.P., et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain, pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 100 (2003) 10529-10533
106. Jaggar S.I., Hasnie F.S., Sellaturay S., and Rice A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76 (1998) 189-199
107. Johnson M.R., and Melvin L.S. The discovery of nonclassical cannabinoid analgetics. In: Mechoulam R. (Ed). Cannabinoids as Therapeutic Agents (1986), CRC Press, Boca Rato 121-145
108. Justinová Z., Tanda G., Redhi G.H., and Goldberg S.R. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology 169 (2003) 135-140
109. Justinová Z., Tanda G., Munzar P., and Goldberg S.R. The opioid antagonist naltrexone reduces the reinforcing effects of Δ9-tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology 173 (2004) 186-194
110. Justinová Z., Solinas M., Tanda G., Redhi G.H., and Goldberg S.R. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci 25 (2005) 5645-5650
111. Justinová Z., Goldberg S.R., Heishman S.J., and Tanda G. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav 81 (2005) 285-299
112. Katona I., Sperlágh B., Sík A., Käfalvi A., Vizi E.S., Mackie K., et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19 (1999) 4544-4558
113. Kearn C.S., and Hilliard C.J. Rat microglial cell express the peripheral-type cannabinoid receptor (CB2) which is negatively coupled to adenylyl cyclase. Proceedings of the Symposium on the Cannbinoids, Burlington, Vermont, International Cannabinoid Research Society 57 (1997)
114. Kishimoto S., Muramatsu M., Gokoh M., Oka S., Waku K., and Sugiura T. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem 137 (2005) 217-223
115. Landa L., and Jurajda M. Acute and repeated exposure to methamphetamine changes expression of CB1 receptor in mesencephalon of the mouse brain. Eur Neuropsychopharmacol 17 Suppl. 4 (2007) S557
116. Landa L., Šlais K., and Šulcová A. Impact of cannabinoid receptor ligands on behavioural sensitization to antiaggressive methamphetamine effects in the model of mouse agonistic behaviour. Neuro endocrinol Lett 27 (2006) 703-710
117. Le Foll B., and Goldberg S.R. Cannabinoid CB1 antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312 (2005) 875-883
118. Lichtman A.H., and Martin B.R. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 258 (1991) 517-523
119. Lichtman A.H., and Martin B.R. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 168 (2005) 691-717
120. Lu Q., Straiker A., Lu Q., and Maguire G. Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Vis Neurosci 17 (2000) 91-95
121. Mackie K. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 28 (2006) 298-306
122. Mackie K., and Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 28 (2006) 298-306
123. Mackie K., and Ross RA. CB2 cannabinoid receptors: new vistas. Br J Pharmacol 153 (2006) 177-178
124. Mailleux P., and Vanderhaeghen J.J. Distribution of the neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48 (1992) 655-688
125. Malan T.P., Ibrahim M.M., Deng H.F., Liu Q., Mata H.P., Vanderah T., et al. Cb2 cannabinoid receptor-mediated peripheral antinociception. Pain 93 (2001) 239-245
126. Malan Jr. T.P., Ibrahim M.M., Vanderah T.W., Makriyannis A., and Porreca F. Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chem Phys Lipids 121 (2002) 191-200
127. Maldonado R., Valverde O., and Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29 (2006) 225-232
128. Marsicano G., and Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11 (1999) 4213
129. Martin B.R. Identification of the endogenous cannabinoid system through integrative pharmacological approaches. J Pharm Exp Ther 301 (2002) 790-796
130. Martin B.R. Role of lipids and lipid signaling in the development of cannabinoid tolerance. Life Sci 77 (2005) 1543-1558
131. Martin B.R., Mechoulam R., and Razdan R.K. Discovery and characterization of endogenous cannabinoids. Life Sci 65 (1999) 573-595
132. Martin B.R., Sim-Selley L.J., and Selley D.E. Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 25 (2004) 325-330
133. Martin W.J., Patrick S.L., Coffin P.O., Tsou K., and Walker J.M. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci 56 (1995) 2103-2109
134. Martin W.J., Hohmann A.G., and Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 16 (1996) 6601-6611
135. Martin W.J., Tsou K., and Walker J.M. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 242 (1998) 33-36
136. Martínez-Orgado J., Fernández-Frutos B., González R., Romero E., Urigüen L., Romero J., et al. Neuroprotection by the cannabinoid agonist WIN-55, 212 in an in vivo newborn rat model of acute severe asphyxia. Mol Brain Res 114 (2003) 132-139
137. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
138. Matsuda L.A., Bonner T.I., and Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327 (1993) 535-550
139. Mauler F., Mittendorf J., Horváth E., and De Vry J. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 302 (2002) 359-368
140. McAllister S.D., Griffin G., Satin L.S., and Abood M.E. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system. J Pharmacol Exp Ther 291 (1999) 618-626
141. Mechoulam R., and Shohami E. HU-211: Cannabinoid neuroprotective agent. In: Grotenhermen F., and Russo E. (Eds). Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (2002), Haworth Press, Binghamton, NY 389-400
142. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 291 (1995) 83-90
143. Mechoulam R., Fride E., and Di Marzo V. Endocannabinoids. Eur J Pharmacol 359 (1998) 1-18
144. Melvin L.S., Milne G.M., Johnson M.R., Subramaniam B., Wilken G.H., and Howlett A.C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 44 (1993) 1008-1015
145. Mitrirattanakul S., Ramakul N., Guerrero A.V., Matsuka Y., Ono T., Iwase H., et al. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126 (2006) 102-114
146. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
147. Nackley A.G., Zvonok A.M., Makriyannis A., and Hohmann A.G. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 92 (2004) 3562-3574
148. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19 (1999) 2987-2995
149. Ohno-Shosaku T., Maejima T., and Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29 (2001) 729-738
150. Oka S., Ikeda S., Kishimoto S., Gokoh M., Yanagimoto S., Waku K., et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. J Leukoc Biol 76 (2004) 1002-1009
151. Oka S., Yanagimoto S., Ikeda S., Gokoh M., Kishimoto S., Waku K., et al. Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13- acetate-induced acute inflammation in mouse ear. J Biol Chem 280 (2005) 18488-18497
152. Onaivi E.S., Chakrabarti A., and Chaudhuri G. Cannabinoid receptor genes. Prog Neurobiol 48 (1996) 275-305
153. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci 1074 (2006) 514-536
154. Oviedo A., Glowa J., and Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 616 (1993) 293-302
155. Pagotto U., and Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 365 (2005) 1363-1364
156. Pagotto U., Vicennati V., and Pasquali R. The endocannabinoid system in the physiopathology of metabolic disorders. Horm Res 67 (2007) 186-190
157. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413 (2001) 527-531
158. Pertwee R.G. The central pharmacology of psychotropic cannabinoids. Pharmacol Ther 36 (1988) 189-261
159. Pertwee R.G. Cannabinoid receptor ligands (1995), Academic Press, London
160. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74 (1997) 129-180
161. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6 (1999) 635-664
162. Pertwee R.G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs 9 (2000) 1553-1571
163. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol 63 (2001) 569-611
164. Pertwee R.G., and Ross T.M. Drugs which stimulate or facilitate central cholinergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 30 (1991) 67-71
165. Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xie X.Q., et al. Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A 96 (1999) 5802-5807
166. Pope H.G., and Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. J Am Med Assoc 275 (1996) 521-527
167. Porter A.C., and Felder C.C. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90 (2001) 45-60
168. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301 (2002) 1020-1024
169. Price T.J., Helesic G., Parghi D., Hargreaves K.M., and Flores C.M. The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience 120 (2003) 155-162
170. Raitio K.H., Salo O.M.H., Nevalainen T., Poso A., Järvinen T., et al. Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands. Curr Med Chem 12 (2005) 1217-1237
171. Ralevic V., Kendall D.A., Randall M.D., and Smart D. Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sci 71 (2002) 2577-2594
172. Rice A.S., Farquhar-Smith W.P., and Nagy I. Endocannabinoids and pain spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fat Acids 66 (2002) 243-256
173. Richardson J.D. Cannabinoids modulate pain by multiple mechanisms of action. J Pain 1 (2000) 2-14
174. Richardson J.D., Aanonsen L., and Hargreaves K.M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 18 (1998) 451-457
175. Richardson J.D., Kilo S., and Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75 (1998) 111-119
176. Richfield E.K., and Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 36 (1994) 577-584
177. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350 (1994) 240-244
178. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive-sensitization view. Addiction 5 (1993) S91-117
179. Rodríguez J.J., Mackie K., and Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in m-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 21 (2001) 823
180. Rodriguez de Fonseca F., Gorriti M., Fernandez R.J., Palomo T., and Ramos J.A. Down regulation of rat brain cannabinoid binding sites after chronic Δ9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47 (1994) 33-40
181. Romero J., Garcia-Palomero E., Castro J.G., Garcia-Gil L., Ramos J.A., and Fernandez-Ruiz J.J. Effects of chronic exposure to Δ9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Mol Brain Res 46 (1997) 100-108
182. Romero J., Lastres-Becker I., De Miguel R., Berrendero F., Ramos J.A., and Fernández-Ruiz J. The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 95 (2002) 137-152
183. Rondon P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 178 (2001) 107-115
184. Ross R.A., Brockie H.C., Stevenson L.A., Murphy V.L., Templeton F., Makriyannis A., et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126 (1999) 665-672
185. Ross R.A., Coutts A.A., McFarlane S.M., Anavi-Goffer S., Irving A.J., Pertwee R.G., et al. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40 (2001) 221-232
186. Rubino T., Vigano D., Massi P., and Parolaro D. Cellular mechanisms of Δ9-tetrahydrocannabinol behavioural sensitization. Eur J Neurosci 17 (2003) 325-330
187. Salio C., Doly S., Fischer J., Franzoni M.F., and Conrath M. Neuronal and astrocytic localization of the cannabinoid receptor-1 in the dorsal horn of the rat spinal cord. Neurosci Lett 329 (2002) 13-16
188. Salzet M. Invertebrate molecular neuroimmune processes. Brain Res Rev 34 (2000) 69-79
189. Sánchez C., De Ceballos M.L., Gómez del Pulgar T., Rueda D., Corbacho C., Velasco G., et al. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res 61 (2001) 5784-5789
190. Sañudo-Peña M.C., Patrick S.L., Khen S., Patrick R.L., Tsou K., and Walker J.M. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci Lett 248 (1998) 171-174
191. Scallet A.C. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav 40 (1991) 671-676
192. Schlicker E., and Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22 (2001) 565-572
193. Schlicker E., Timm J., Zentner J., and Göthert M. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiedebergs Arch Pharmakol 356 (1997) 583-589
194. Shatz A.R., Lee M., Condie R.B., Pulaski J.T., and Kaminski N.E. Cannabinoid receptors CB1 and CB2, a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142 (1997) 278-287
195. Shen M., Piser T.M., Seybold V.S., and Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16 (1996) 4322-4334
196. Showalter V.M., Compton D.R., Martin B.R., and Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278 (1996) 989-999
197. Siegling A., Hofmann H.A., Denzer D., Mauler F., and De Vry J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415 (2001) 5-7
198. Skaper S.D., Buriani A., Dal Toso R., Petrelli L., Romanello S., Facci L., et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A 93 (1996) 3984-3989
199. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., and Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270 (1994) 219-227
200. Ständer S., Schmelz M., Metze D., Luger T., and Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38 (2005) 177-188
201. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215 (1995) 89-97
202. Sugiura T., Kondo S., Kishimoto S., Miyashita T., Nakane S., Kodata T., et al. Evidence that 2-arachidonylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. J Biol Chem 275 (2000) 605-612
203. Suigiura T., and Waku K. 2-Arachidonoylglycerol and cannabinoid receptors. Chem Phys Lipids 108 (2000) 89-106
204. Sulcova A., Mechoulam R., and Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 59 (1998) 347-352
205. Szabo B., Nordheim U., and Niederhoffer N. Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 297 (2001) 819-826
206. Tanda G., Munzar P., and Goldberg S.R. Self-administration behavior is maintained by psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3 (2000) 1073-1074
207. Tsou K., Lowitz K.A., Hohmann A.G., Martin W.J., Hathaway C.B., Bereiter D.A., et al. Suppression of noxious stimulus-evoked expression of FOS protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience 70 (1996) 791-798
208. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1997) 393-411
209. Tsou K., Mackie K., Sañudo-Peña M.C., and Walker J.M. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 93 (1999) 969
210. van der Stelt M., Veldhuis W.B., Bär P.R., Veldink G.A., Vliegenthart J.F.G., and Nicolay K. Neuroprotection by Δ9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 21 (2001) 6475-6479
211. Vaughan C.W., and Christie M.J. An analgesic role for cannabinoids. Med J Aust 173 (2000) 270-272
212. Vinklerova J., Novakova J., and Sulcova A. Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. J Psychopharmacol 16 (2002) 139-143
213. Wagner J.A., Jarai Z., Batkai S., and Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423 (2001) 203-210
214. Walker J.M., Huang S.M., Strangman N.M., Tsou K., and Sañudo-Peña M.C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 96 (1999) 12198-12203
215. Walker J.M., Krey J.F., Chu C.J., and Huang S.M. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 121 (2002) 159-172
216. Walter L., and Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol 141 (2004) 775-785
217. Welch S.P., Thomas C., and Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 272 (1995) 310-321
218. Welch S.P., Huffman J.W., and Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 286 (1998) 1301-1308
219. Westlake T.M., Howlett A.C., Bonner T.I., Matsuda L.A., and Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiographic and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63 (1994) 637-652
220. Williamson E.M., and Evans F.J. Cannabinoids in clinical practice. Drug 60 (2000) 1303-1314
221. Wilson R.I., and Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (Lond) 410 (2001) 588-592
222. Wise L.E., Shelton C.C., Cravatt B.F., Martin B.R., and Lichtman A.H. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. Eur J Pharmacol 557 (2007) 44-48
223. Zangen A., Solinas M., Ikemoto S., Goldberg S.R., and Wise R.A. Two brain sites for cannabinoid reward. J Neurosci 26 (2006) 4901-4907
224. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999) 452-457